Adquisición vacuna frente al virus respiratorio sincitial (VRS)

Secretaría General de la Consejería de Sanidad de la Junta de Comunidades de Castilla-La Mancha·Toledo, Spain·EUR 7.9M·Expired · Jul 10, 2026·Open·Supplies

High valueStructured notice only

Original notice title

Spain – Vaccines – Adquisición vacuna frente al virus respiratorio sincitial (VRS)

70/100

Opportunity Score

Needs reviewMedium complexity

SuppliesExpired

Why this score?

Opportunity

70 / 100

Complexity

60 / 100

Risk factors

Structured data indicates EU-funded, but XML notice states 'no-eu-funds'. This could affect contract terms or condition...

No procurement documents were analyzed; essential details (e.g., technical specs, contract terms) are unknown.

Deep Portfolio Analysis

Deep Company Fit Analysis

Uses:

Description
Industries & Services
Capabilities
Market & Experience
Certifications

Overview

Moderate opportunity

Key Facts

EUR 7.9M estimated value
Supplies contract
1 lot
Duration 13 MONTH
Supply of VRS vaccine for adult and high-risk populations
Duration of 13 months

Show full summary

Open tender for the supply of a vaccine against Respiratory Syncytial Virus (VRS) for adult and high-risk populations in Castilla-La Mancha, Spain. Single lot, estimated value €7,920,000, 13-month contract. EU-funded according to structured data, but XML notice indicates no EU funds. Award criteria 60% quality, 40% price. Selection criteria include annual turnover and references. Deadline 10 July 2026.

Risks

Structured data indicates EU-funded, but XML notice states 'no-eu-funds'. This could affect contract terms or condition...

No procurement documents were analyzed; essential details (e.g., technical specs, contract terms) are unknown.

Analysis may be incomplete

Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.

Key Requirements

Eligibility

Annual turnover and references required for eligibility

Administrative

Open procedure, electronic submission required
Language: Spanish

Requirements may be incomplete.

Award Criteria

Lot 1

Quality: Co-administration with flu and COVID-19 vaccines (8 points) — 8%Quality: Maximum demonstrated immunity duration (12 points) — 12%Quality: Efficacy evidence in vulnerable subgroups (12 points) — 12%Quality: Level of clinical efficacy evidence (12 points) — 12%Price: Economic offer (40 points) — 40%Quality: Validity period (10 points) — 10%Quality: Pharmaceutical presentation (2 points) — 2%Quality: Replacement for cold chain breakage (4 points) — 4%